Biopharmaceuticals, which leverage genetic engineering and cell culture technologies to target specific ailments such as cancer more effectively than traditional drugs, require significant investment in cell cultivation facilities. The trend towards outsourcing has grown as pharmaceutical firms prioritize research and development over manufacturing.
In this growing market, Fujifilm aims to increase its production capacity fivefold, reaching about 750,000 liters by 2028. This expansion also includes planned investments in Japan and Europe, reinforcing its global supply chain capabilities.
Ranked fourth globally in 2022, Fujifilm is ramping up its efforts to compete with industry leaders like Lonza, Wuxi Biologics, and Samsung Biologics. The company’s sales in this sector are projected to hit 500 billion yen by March 2029, marking a substantial increase from the previous fiscal year.
The global market for biopharmaceuticals is anticipated to surge to $27.9 billion by 2029, an 80% increase from 2024. Fujifilm’s cumulative investment in this area is expected to exceed 1 trillion yen ($6.5 billion), underscoring its commitment to becoming a leading force in the biopharmaceutical manufacturing industry since its entry in 2011.
